# Oric Pharmaceuticals Inc. (ORIC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.86, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Oric Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.5×**. The shares trade at 3.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.4%** (5-yr avg -19.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -33.7%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 19.7%**. Earnings per share rose 19.7%.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Current ratio: 14.13** (quick 14.13). Current assets cover the next year's liabilities 14.13 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Oric Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Oric Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $20.67 (+61% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 19.4%** (YTD 57.2%, 3-mo 71.5%). The shares are up 19.4% over twelve months including dividends.
- **From 52-week high: -13.9%** (77.9% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.47** (volatility 86%). Beta of 1.47 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ORIC · Page: https://foliofundamentals.com/stocks/oric

Not investment advice.